Multiple myeloma - haematology - SA Health Approved Cancer Chemotherapy Protocol Register
Waldenstrom macroglobulinaemia
| Protocol | Administration at chemotherapy unit level | Review Date |
|---|---|---|
| Waldenstrom macroglobulinaemia DRC (dexamethasone RITUximab CYCLOPHOSPHamide) | Medium | August 2024 |
Multiple myeloma
| Protocol | Administration at chemotherapy unit level | Review Date |
|---|---|---|
| AL amyloidosis melphalan and dexamethasone oral | Medium Cycle 1. Low Cycle 2 onwards if patient tolerates | March 2022 |
| Multiple myeloma and AL amyloidosis CTD (CYCLOPHOSPHamide thalidomide dexamethasone) oral | Low | February 2023 |
| Multiple myeloma
carfilzomib and dexamethasone twice weekly
|
High cycle 1, Medium cycle 2 onwards if patient tolerates | February 2022 |
| Multiple myeloma
carfilzomib and dexamethasone weekly
|
High cycle 1, Medium cycle 2 onwards if patient tolerates | February 2022 |
| Multiple Myeloma bortezomib, lenalidomide and dexamethasone (VRd) 21-day protocol First line treatment of newly diagnosed myeloma patients in place of Vd (bortezomib-dex) or Rd (lenalidomide-dex) where appropriate. For more information on this protocol please contact the SA Health Cancer Drug Committee |
Low | June 2022 |
| Multiple Myeloma bortezomib, lenalidomide and dexamethasone (VRd) 28-day protocol First line treatment of newly diagnosed transplant-eligible patients. For more information on this protocol please contact the SA Health Cancer Drug Committee. |
Low | June 2022 |
| Multiple Myeloma bortezomib, lenalidomide and dexamethasone (VRd) 35-day protocol First line therapy. This protocol provides a modified VRd (VRd-Lite) which can be more safely delivered to elderly and/or frail newly-diagnosed transplant-ineligible multiple myeloma patients. For more information on this protocol please contact the SA Health Cancer Drug Committee. |
Low | June 2022 |
| Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) | Low | February 2022 |
| Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) weekly | Low | February 2022 |
| Multiple myeloma daratumumab | High cycle 1, Medium cycle 2 onwards if patient tolerates | August 2024 |
| Multiple myeloma daratumumab maintenance | High cycle 1, Medium cycle 2 onwards if patient tolerates | August 2020 |
| Multiple myeloma DRd (daratumumab lenalidomide dexamethasone) | High cycle 1, Medium cycle 2 onwards if patient tolerates | August 2020 |
| Multiple myeloma DT-PACE (dexamethasone thalidomide cISplatin DOXOrubicin CYCLOPHOSPHamide etoposide) | High | August 2024 |
| Multiple myeloma DVd (daratumumab bortezomib dexamethasone)The SAHCDC has endorsed the use of weekly dosing of Bortezomib (Day 1, 8 and 15) for patients unable/unlikely to tolerate twice weekly dosing” | High cycle 1, Medium cycle 2 onwards if patient tolerates | February 2022 |
| Multiple myeloma D-VMP (daratumumab bortezomib melphalan prednisolone) | High cycle 1, Medium cycle 2 onwards if patient tolerates | August 2020 |
| Multiple myeloma ixazomib lenalidomide and dexamethasone oral | Low | February 2021 |
| Multiple myeloma lenalidomide and dexamethasone oral | Low | February 2022 |
| Multiple myeloma lenalidomide
maintenance post autologous transplant
|
Low | August 2021 |
| Multiple myeloma MPT (melphalan prednisolone thalidomide) oral | Low | February 2023 |
| Multiple myeloma pomalidomide and dexamethasone oral | Low | February 2022 |
| Multiple myeloma PVd (pomalidomide bortezomib and dexamethasone)3 | Low | August 2021 |
| Multiple myeloma thalidomide and dexamethasone oral | Low | February 2023 |
Notes
- Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
- Fluorouracil pumps may be connected/disconnected at low-risk units
- Non-formulary drug included in the protocol
- Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.
